SIRS - Schizophrenia International Research Society

March 25-29
Florence, Italy

Tardive Dyskinesia

Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Tardive Dyskinesia: A Multicenter Phase 4 Study 

Authors:
Qijing Bo, Anning Li, Wenwen Dun, Xiaoying Zhang, Zheng Wang, Jie Li, Lili Wang, Wei Li, Na Li, Yunlong Tan, Xiaojin Xu, Jianye Qu, Yang Li, Ge Zhang, Kasim Tugrul Ustundag, Aviva Peyser Levin, Rinat Ribalov, Weixiu Luo, Roy Eshet, Mikhail Zeygarnik, Shimin Bi, Gang Wang 

Download the poster

Health-related social needs in individuals with schizophrenia and tardive dyskinesia in the IMPACT-TD Registry

 

Authors:
Stacy Finkbeiner, Martijn Konings, Diana Klakotskaia, Daisy Yu, Carolyn Rainville, Mark Henegar 

Download the poster

 

Long Acting Injectable

 

Real-World Assessment of Cardiometabolic Characteristics in US Medicaid-Covered Adults Living With Schizophrenia During Oral Olanzapine Treatment, Based on Prior Antipsychotic Use 

 

Authors:
John Kane, Sangtaeck Lim, Tomas Holmqvist, Handing Xie, Kelli Franzenburg, Lynda Krasenbaum, Rolf Hansen, Jose Rubio 

Download the poster

Long-Term Safety of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults with Schizophrenia: Results from the Phase 3 SOLARIS Trial 

 

Authors:
Christoph U. Correll, Ken Shulman, Tamar Bar-Nur, Rotem Gidron-Budovsky, Nir Sharon, Ayellet Jehassi, Kelli R. Franzenburg, Mark Suett, Ortal Pelleg, Helena Knebel, Avia Merenlender-Wagner, Eran Harary, Anna Elgart 

Download the poster

Long-Term Durability of Effect with Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults with Schizophrenia: Results from up to 48 Weeks Open-Label Treatment in the Phase 3 SOLARIS Trial 

 

Authors:
Christoph U. Correll, Ken Shulman, Tamar Bar-Nur, Rotem Gidron-Budovsky, Nir Sharon, Ayellet Jehassi, Kelli R. Franzenburg, Mark Suett, Ortal Pelleg, Helena Knebel, Avia Merenlender-Wagner, Eran Harary, Anna Elgart 

Download the poster

Exposure–Response Efficacy and Safety Analysis of Subcutaneous LAI Olanzapine (TV-44749): Clinical Application for Dosing and Switching Strategies 

 

Authors:
Nikunjkumar Patel, Annabelle Walz, Itay Perlstein, Avia Merenlender Wagner, Helena Knebel, Anna Elgart, Rajendra Singh 

Download the poster

Exposure–Response Relationship of Once-Monthly Subcutaneous Olanzapine (TV-44749) for Clinical and Functional Outcomes in Schizophrenia 

 

Authors:
Nikunjkumar Patel, Christian Toensing, Martin Fink, Itay Perlstein, Avia Merenlender Wagner, Anna Elgart, Rajendra Singh 

Download the poster

Joint Population Pharmacokinetic Model of Olanzapine Following Oral,  Intramuscular, and Subcutaneous (TV-44749) Administration to Support Dose Recommendations and Switching Strategies 

 

Authors:
Nikunjkumar Patel, Henning Schmidt, Itay Perlstein, Avia Merenlender Wagner, Anna Elgart, Rajendra Singh 

Download the poster

Long-Term Quality of Life of Adults with Schizophrenia Treated with Subcutaneous Long-Acting Injectable Olanzapine (TV-44749): Results from the Open-Label Period (≤48 weeks) of the Phase 3 SOLARIS Trial 

 

Authors:
Christoph U. Correll, Tamar Bar-Nur, Rotem Gidron-Budovsky, Nir Sharon, Ayellet Jehassi, Kelli R. Franzenburg, Mark Suett, Ortal Pelleg, Avia Merenlender-Wagner, Eran Harary, Anna Elgart, Sangtaeck Lim 

Download the poster

Seeing Through the Patient’s Eyes: Generative Artificial Intelligence as a Window Into the Experience of Living With Schizophrenia 

 

Authors:
Alex Gotler, Noam Mairon, Ariel Oren, Danny Lesmy, Michael Reich, Anna Elgart, Mark Suett, Eran Harary 

Download the poster